These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 15686539)

  • 1. Identification of Fmoc-beta-Ala-OH and Fmoc-beta-Ala-amino acid-OH as new impurities in Fmoc-protected amino acid derivatives.
    Hlebowicz E; Andersen AJ; Andersson L; Moss BA
    J Pept Res; 2005 Jan; 65(1):90-7. PubMed ID: 15686539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fmoc-2-mercaptobenzothiazole, for the introduction of the Fmoc moiety free of side-reactions.
    Isidro-Llobet A; Just-Baringo X; Ewenson A; Alvarez M; Albericio F
    Biopolymers; 2007; 88(5):733-7. PubMed ID: 17385207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Formation of Fmoc-beta-alanine during Fmoc-protections with Fmoc-OSu.
    Obkircher M; Stähelin C; Dick F
    J Pept Sci; 2008 Jun; 14(6):763-6. PubMed ID: 18219706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The aspartimide problem in Fmoc-based SPPS. Part I.
    Mergler M; Dick F; Sax B; Weiler P; Vorherr T
    J Pept Sci; 2003 Jan; 9(1):36-46. PubMed ID: 12587881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The aspartimide problem in Fmoc-based SPPS. Part III.
    Mergler M; Dick F
    J Pept Sci; 2005 Oct; 11(10):650-7. PubMed ID: 15849777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aza-amino acid scanning of secondary structure suited for solid-phase peptide synthesis with fmoc chemistry and aza-amino acids with heteroatomic side chains.
    Boeglin D; Lubell WD
    J Comb Chem; 2005; 7(6):864-78. PubMed ID: 16283795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 2-(N-Fmoc)-3-(N-Boc-N-methoxy)-diaminopropanoic acid, an amino acid for the synthesis of mimics of O-linked glycopeptides.
    Carrasco MR; Brown RT; Doan VH; Kandel SM; Lee FC
    Biopolymers; 2006; 84(4):414-20. PubMed ID: 16508952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Problem of aspartimide formation in Fmoc-based solid-phase peptide synthesis using Dmab group to protect side chain of aspartic acid.
    Ruczyński J; Lewandowska B; Mucha P; Rekowski P
    J Pept Sci; 2008 Mar; 14(3):335-41. PubMed ID: 17975850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel N omega-xanthenyl-protecting groups for asparagine and glutamine, and applications to N alpha-9-fluorenylmethyloxycarbonyl (Fmoc) solid-phase peptide synthesis.
    Han Y; Solé NA; Tejbrant J; Barany G
    Pept Res; 1996; 9(4):166-73. PubMed ID: 8914163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The investigation of Fmoc-cysteine derivatives in solid phase peptide synthesis.
    McCurdy SN
    Pept Res; 1989; 2(1):147-52. PubMed ID: 2577698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preparation, isolation, and characterization of Nalpha-Fmoc-peptide isocyanates: solution synthesis of oligo-alpha-peptidyl ureas.
    Sureshbabu VV; Patil BS; Venkataramanarao R
    J Org Chem; 2006 Sep; 71(20):7697-705. PubMed ID: 16995676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of C-terminal modification on the self-assembly and hydrogelation of fluorinated Fmoc-Phe derivatives.
    Ryan DM; Doran TM; Anderson SB; Nilsson BL
    Langmuir; 2011 Apr; 27(7):4029-39. PubMed ID: 21401045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preparation of protected peptidyl thioester intermediates for native chemical ligation by Nalpha-9-fluorenylmethoxycarbonyl (Fmoc) chemistry: considerations of side-chain and backbone anchoring strategies, and compatible protection for N-terminal cysteine.
    Gross CM; Lelièvre D; Woodward CK; Barany G
    J Pept Res; 2005 Mar; 65(3):395-410. PubMed ID: 15787970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and application of Fmoc-His(3-Bum)-OH.
    Mergler M; Dick F; Sax B; Schwindling J; Vorherr TH
    J Pept Sci; 2001 Sep; 7(9):502-10. PubMed ID: 11587189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An efficient and highly selective deprotection of N-Fmoc-alpha-amino acid and lipophilic N-Fmoc-dipeptide methyl esters with aluminium trichloride and N,N-dimethylaniline.
    Di Gioia ML; Leggio A; Le Pera A; Siciliano C; Liguori A; Sindona G
    J Pept Res; 2004 Apr; 63(4):383-7. PubMed ID: 15102056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Introducing chemical functionality in Fmoc-peptide gels for cell culture.
    Jayawarna V; Richardson SM; Hirst AR; Hodson NW; Saiani A; Gough JE; Ulijn RV
    Acta Biomater; 2009 Mar; 5(3):934-43. PubMed ID: 19249724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N-->O-Acyl shift in Fmoc-based synthesis of phosphopeptides.
    Eberhard H; Seitz O
    Org Biomol Chem; 2008 Apr; 6(8):1349-55. PubMed ID: 18385841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of the excluded protecting group (EPG) method for peptide synthesis.
    Head DB; Dong JZ; Burton JA
    J Pept Res; 2005 Mar; 65(3):384-94. PubMed ID: 15787969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Convenient route to enantiopure fmoc-protected morpholine-3-carboxylic acid.
    Sladojevich F; Trabocchi A; Guarna A
    J Org Chem; 2007 May; 72(11):4254-7. PubMed ID: 17465566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative studies of Nsc and Fmoc as N(alpha)-protecting groups for SPPS.
    Ramage R; Jiang L; Kim YD; Shaw K; Park JL; Kim HJ
    J Pept Sci; 1999 Apr; 5(4):195-200. PubMed ID: 10323199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.